MARKET

RVNC

RVNC

Revance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.80
-0.26
-1.00%
After Hours: 25.80 0 0.00% 16:35 03/03 EST
OPEN
26.13
PREV CLOSE
26.06
HIGH
26.65
LOW
25.52
VOLUME
776.42K
TURNOVER
--
52 WEEK HIGH
34.62
52 WEEK LOW
11.78
MARKET CAP
1.84B
P/E (TTM)
-5.3247
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dermal Fillers Market Size worth USD 6.64 Billion by 2027 at 9.3% CAGR; High Demand for Minimally Invasive Surgeries to Boost Growth: Fortune Business Insights(TM)
The global dermal fillers market is set to gain traction from the increasing usage of hyaluronic acid dermal fillers as they are considered to be the gold standard material for facial fillers, such as restoration of volume/fullness, scar treatment, lip enh...
GlobeNewswire · 10h ago
10-K: REVANCE THERAPEUTICS, INC.
Edgar Online - (EDG = 10Q, 10K) · 6d ago
Botulinum Toxin Industry Size, Share, Global Development and Forecast, Top Companies, Industry Current Trends, Application, Growth Factors to 2025 Research Report
Feb 25, 2021 (The Expresswire) -- Global Botulinum Toxin Market Research Report Focuses on the key global Botulinum Toxin manufacturers, to define, describe...
The Express Wire · 6d ago
Revance to Participate in Upcoming Virtual Healthcare Conferences
Revance to Participate in Upcoming Virtual Healthcare Conferences
Business Wire · 02/24 21:05
Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography
Dublin, Feb 24, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025"...
GlobeNewswire · 02/24 10:14
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling ...
BusinessWire · 02/23 21:05
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
DJ Revance Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/23 12:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RVNC. Analyze the recent business situations of Revance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RVNC stock price target is 37.80 with a high estimate of 55.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 226
Institutional Holdings: 60.19M
% Owned: 84.32%
Shares Outstanding: 71.38M
TypeInstitutionsShares
Increased
49
6.17M
New
50
1.00M
Decreased
45
2.58M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Angus Russell
President/Chief Executive Officer/Director
Mark Foley
Chief Financial Officer
Tobin Schilke
Chief Operating Officer
Abhay Joshi
Senior Vice President/General Counsel/Secretary
Dwight Moxie
Other
Dustin Sjuts
Director
Aubrey Rankin
Independent Director
Jill Beraud
Independent Director
Robert Byrnes
Independent Director
Julian Gangolli
Independent Director
Phyllis Gardner
Independent Director
Chris Nolet
Independent Director
Philip Vickers
  • Dividends
  • Splits
  • Insider Activity
No Data
About RVNC
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.